TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25001960

Group type: EXPERIMENTAL
Intervention: Testosterone response following the Trier Social Stress Test (TSST)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Lower basal cortisol
Number of subjects: 85
Study: 22474534

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Tachibana‐Ryojutsu
Number of subjects: 47
Study: 20526200

Group type: EXPERIMENTAL
Intervention: 8-year continuous estrogen-plus-progestin use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dynamic treatment regimen (take hormone therapy until certain adverse events become apparent, then stop)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No use of hormone therapy
Number of subjects: 0
Study: 18465110

Group type: EXPERIMENTAL
Intervention: Acupuncture with electrical stimulation
Number of subjects: 92

Group type: COMPARATOR
Intervention: Mock TENS (placebo)
Number of subjects: 92
Study: 16104901

Group type: EXPERIMENTAL
Intervention: DN-101 (high-dose oral calcitriol) combined with docetaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo combined with docetaxel
Number of subjects: 0
Study: 14651247

Group type: EXPERIMENTAL
Intervention: Bent-handled long-handled sponge
Number of subjects: 38

Group type: COMPARATOR
Intervention: Straight-handled long-handled sponge
Number of subjects: 38
Study: 10368039

Group type: EXPERIMENTAL
Intervention: Oxygen inhalation during radiotherapy sessions
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Oxygen inhalation during all radiotherapy sessions
Number of subjects: 208

Group type: COMPARATOR
Intervention: Breathing air (control group)
Number of subjects: 208
Study: 7575311

Group type: EXPERIMENTAL
Intervention: Alcohol (mean BAC = 0.037%)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Alcohol and Placebo
Number of subjects: 12
Study: 2265047

Group type: EXPERIMENTAL
Intervention: Halothane anaesthesia
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Enflurane anaesthesia
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Isoflurane anaesthesia
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Halothane, Enflurane, Isoflurane at 1.25 MAC
Number of subjects: 15

Group type: COMPARATOR
Intervention: Halothane, Enflurane, Isoflurane
Number of subjects: 15
Study: 6109345

Group type: EXPERIMENTAL
Intervention: Tofisopam (100 mg single dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diazepam (10 mg single dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diazepam (10 mg) + Ethanol (0.8 g/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tofisopam (100 + 50 + 50 + 100 mg repeated doses)
Number of subjects: 12
Study: 31839705

Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 100/62.5/25 µg
Number of subjects: 378

Group type: COMPARATOR
Intervention: FF/VI 100/25 µg
Number of subjects: 378

Group type: COMPARATOR
Intervention: UMEC/VI 62.5/25 µg
Number of subjects: 378
Study: 27566597

Group type: EXPERIMENTAL
Intervention: Shared care cardiac rehabilitation (SC-CR)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Hospital-based cardiac rehabilitation (H-CR)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Shared care cardiac rehabilitation (SC-CR) and Hospital-based cardiac rehabilitation (H-CR)
Number of subjects: 212
Study: 25680727

Group type: EXPERIMENTAL
Intervention: 40 keV Mono+
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 55 keV Mono+
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 70 keV Mono+
Number of subjects: 44

Group type: COMPARATOR
Intervention: M_0.3 (30% 80 kV)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Contrast-to-noise ratio (CNR) at 40 keV
Number of subjects: 44
Study: 23364608

Group type: EXPERIMENTAL
Intervention: XEN-D0101
Number of subjects: 2
Study: 21085029

Group type: EXPERIMENTAL
Intervention: Dorsal locking plate
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dorsal nonlocking plate
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Volar locking plate
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Volar nonlocking plate
Number of subjects: 32
Study: 19563641

Group type: EXPERIMENTAL
Intervention: Resistance/impact loading exercise
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Resistance/cardiovascular exercise
Number of subjects: 195

Group type: COMPARATOR
Intervention: Usual care/delayed exercise
Number of subjects: 195
Study: 17318527

Group type: EXPERIMENTAL
Intervention: Enteral nimodipine (60 mg tablet/suspension at 4-h intervals)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Intravenous nimodipine (2 mg/h continuous infusion)
Number of subjects: 17
Study: 15241347

Group type: EXPERIMENTAL
Intervention: Pranlukast 300 mg twice daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10832772

Group type: EXPERIMENTAL
Intervention: Secretin (2 IU/kg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 9351614

Group type: EXPERIMENTAL
Intervention: salmeterol 50 microg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: fluticasone 250 microg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: combination of salmeterol and fluticasone
Number of subjects: 46

Group type: COMPARATOR
Intervention: healthy control subjects
Number of subjects: 46
Study: 8183178

Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (SCT) (100 IU daily) plus oral calcium
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3963018

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (200 mg total daily dose, administered four times a day)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg total daily dose, administered twice a day)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (up to 300 mg per day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 57
Study: 31137095

Group type: EXPERIMENTAL
Intervention: Group B1 (sound therapy for normal to mild hearing loss)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Group A2 (sound therapy for moderate to profound hearing loss)
Number of subjects: 56
Study: 30292867

Group type: EXPERIMENTAL
Intervention: High-resolution cameras and object-detection algorithm for seatbelt enforcement; capacity trainings for law enforcement; infrastructure renovation; social marketing campaigns.
Number of subjects: 77641
Study: 27895466

Group type: EXPERIMENTAL
Intervention: CKD‐519 (25, 50, 100, 200, or 400 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24763877

Group type: EXPERIMENTAL
Intervention: Prophylactic accessory-pathway ablation
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no ablation)
Number of subjects: 110
Study: 23047378

Group type: EXPERIMENTAL
Intervention: Nissen fundoplication
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Toupet fundoplication
Number of subjects: 100
Study: 20926833

Group type: EXPERIMENTAL
Intervention: AIN457 (3 to 10 mg/kg, intravenously)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 18540868

Group type: EXPERIMENTAL
Intervention: Coping Skills Training (CST)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Group Education (GE)
Number of subjects: 111
Study: 15838760

Group type: EXPERIMENTAL
Intervention: Oral Sialogogum
Number of subjects: 27

Group type: COMPARATOR
Intervention: Non-parallel imaging technique
Number of subjects: 27
Study: 12466334

Group type: EXPERIMENTAL
Intervention: Discontinuation of long-term GH treatment
Number of subjects: 56
Study: 10769103

Group type: EXPERIMENTAL
Intervention: Nerve root injection of 0.10 g of lidocaine hydrochloride and 3.75 mg of cortivazol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Interspinous injection of 0.10 g of lidocaine hydrochloride and 3.75 mg of cortivazol
Number of subjects: 30
Study: 8991563

Group type: EXPERIMENTAL
Intervention: CPAP breathing (10 cm H20 for 25 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: BiPAP breathing (10/4 cm H20 for 25 min)
Number of subjects: 10
Study: 1728626

Group type: EXPERIMENTAL
Intervention: 4-week home-based nutrition education program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 6741440

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 100

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 100
Study: 31130480

Group type: EXPERIMENTAL
Intervention: Early functional rehabilitation (FG)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cast immobilization (IG)
Number of subjects: 41
Study: 28432193

Group type: EXPERIMENTAL
Intervention: NSAID (2 mg/kg flunixin meglumine for three consecutive days)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Antimicrobial (6 mg/kg gamithromycin)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: NSAID (2 mg/kg flunixin meglumine)
Number of subjects: 154
Study: 25824185

Group type: EXPERIMENTAL
Intervention: Commercial weight-loss programme via GP referral
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Referral by GP and follow-up assessment appointments
Number of subjects: 29
Study: 23505169

Group type: EXPERIMENTAL
Intervention: 3 g/day of IQP G‐002AS
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 21209559

Group type: EXPERIMENTAL
Intervention: Social peer mentoring program (SPM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wait-list control (WL)
Number of subjects: 30
Study: 18993033

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Overall treatment effect
Number of subjects: 164
Study: 16836598

Group type: EXPERIMENTAL
Intervention: Cannabis and psychosis therapy (CAP)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Psychoeducation (PE)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both CAP and PE
Number of subjects: 47
Study: 14503053

Group type: EXPERIMENTAL
Intervention: TCM group (Chinese drug medication according to patients' syndrome differentiation)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: WM group (chemotherapy)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: TCM-WM group (combined TCM and WM treatment)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Comparison between TCM-WM group and TCM/WM groups
Number of subjects: 120
Study: 11768164

Group type: EXPERIMENTAL
Intervention: 300 mg DHA
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 600 mg DHA
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 8996138

Group type: EXPERIMENTAL
Intervention: Cisplatin plus ifosfamide (CIFX)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Cisplatin
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Cisplatin plus mitolactol (C + M)
Number of subjects: 438
Study: 7778797

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (ureidopenicillins, cephamycins, and other antibacterial agents active on Gram negative rods and anaerobes) administered as a preoperative flash at anaesthesia induction, followed by a second injection if the procedure duration exceeds 3 hours.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Broad spectrum antibiotic prophylaxis for extended hysterectomy for cancer.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibacterial prophylaxis in mastectomies.
Number of subjects: 0
Study: 2962589

Group type: EXPERIMENTAL
Intervention: Phosphonoformate (PFA) intravenous infusion for 3 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (4 untreated patients)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Phosphonoformate (PFA) intravenous infusion
Number of subjects: 11
Study: 2653086

Group type: EXPERIMENTAL
Intervention: Budesonide via Turbuhaler
Number of subjects: 28

Group type: COMPARATOR
Intervention: Budesonide via MDI
Number of subjects: 28
Study: 30963301

Group type: EXPERIMENTAL
Intervention: Left ventricular pacing through coronary sinus branch
Number of subjects: 60

Group type: COMPARATOR
Intervention: Right ventricular apical pacing (control)
Number of subjects: 60
Study: 26889691

Group type: EXPERIMENTAL
Intervention: Balance training with computer-based visual feedback (BTVF), 4 sessions (2 sessions/day, each session = 15 min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 14
Study: 26149448

Group type: EXPERIMENTAL
Intervention: Oral Chinese herbal formula (Pei Tu Qing Xin granules; PTQX)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 24592780

Group type: EXPERIMENTAL
Intervention: 36-Hz whole-body vibration (WBV)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 46-Hz whole-body vibration (WBV)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 21677054

Group type: EXPERIMENTAL
Intervention: Protein-energy supplements (1015 kcal and 22 g protein/d) provided to pregnant women from 20 weeks gestation until delivery
Number of subjects: 1617

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1.5 g/d) provided to pregnant women from 20 weeks gestation until delivery
Number of subjects: 1617

Group type: COMPARATOR
Intervention: Lactating women receiving no protein-energy supplements (control group for protein-energy trial)
Number of subjects: 1617
Study: 19594505

Group type: EXPERIMENTAL
Intervention: ziprasidone
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: haloperidol
Number of subjects: 434

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: ziprasidone, haloperidol, or placebo
Number of subjects: 434
Study: 17447391

Group type: EXPERIMENTAL
Intervention: Mitomycin C
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 16344225

Group type: EXPERIMENTAL
Intervention: Gated O‐15‐labeled CO PET
Number of subjects: 34

Group type: COMPARATOR
Intervention: Cardiovascular magnetic resonance imaging (MRI)
Number of subjects: 34
Study: 11182048

Group type: EXPERIMENTAL
Intervention: alphaD3 (1alpha (OH) D3) administered to 18 patients
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (11 patients, untreated)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: alphaD3 (total dose > 1,500 microg)
Number of subjects: 29
Study: 9383487

Group type: EXPERIMENTAL
Intervention: Fast injection of buffered lidocaine
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Slow injection of buffered lidocaine
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Fast injection of unbuffered lidocaine
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Slow injection of unbuffered lidocaine
Number of subjects: 29
Study: 7899712

Group type: EXPERIMENTAL
Intervention: Laser photocoagulation (argon green laser, 100-microns spot at 100 mW for 0.1 sec)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 20
Study: 3310018

Group type: EXPERIMENTAL
Intervention: Alprazolam (2.33 mg daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dothiepin hydrochloride (115 mg daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dothiepin hydrochloride
Number of subjects: 100
Study: 29185896

Group type: EXPERIMENTAL
Intervention: E-Learning Group (interactive e-learning case-based module)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional Group (lecture)
Number of subjects: 0
Study: 26874076

Group type: EXPERIMENTAL
Intervention: Elafibranor 120 mg
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study: 25010237

Group type: EXPERIMENTAL
Intervention: Smartphone intervention (specific devices not detailed, but included iPhone and BlackBerry)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Smartphone intervention
Number of subjects: 89
Study: 22105056

Group type: EXPERIMENTAL
Intervention: Supervised resistance training group (SG)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Video training group (VG)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 38
Study: 20307768

Group type: EXPERIMENTAL
Intervention: Bone trap used to harvest bone debris during implant preparation (group A)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Bone scraper used to harvest cortical bone chips (group B)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 61
Study: 18515777

Group type: EXPERIMENTAL
Intervention: Investigational medicinal product (statins)
Number of subjects: 84
Study: 15956633

Group type: EXPERIMENTAL
Intervention: Fish oil, 1.8 g/d, 72% omega‐3 PUFAs
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 12525716

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a 30 microg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a 60 microg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 11407290

Group type: EXPERIMENTAL
Intervention: Isoflurane (0.5 MAC) in 67% N2O‐33% O2 and fentanyl + droperidol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propofol (8 mg/kg/h) infusion combined with 67% N2O‐33% O2 and fentanyl + droperidol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 24

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 24
Study: 9297265

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerine (Nitroderm NNS 5)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Acetylsalicylic acid and curantil
Number of subjects: 61
Study: 8427863

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 20
Study: 3685881

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy
Number of subjects: 9

Group type: COMPARATOR
Intervention: Anticholinergics (early postoperative period)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Anticholinergics (1 year after operation)
Number of subjects: 9
Study: 30273622

Group type: EXPERIMENTAL
Intervention: Topical prostaglandin analog (latanoprost)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 350
Study: 28275100

Group type: EXPERIMENTAL
Intervention: Small-Quantity Lipid-Based Nutrient Supplements (SQ-LNSs; 20 g with 22 micronutrients/d)
Number of subjects: 1320

Group type: EXPERIMENTAL
Intervention: Multiple Micronutrients (MMNs; 18 vitamins and minerals/d)
Number of subjects: 1320

Group type: EXPERIMENTAL
Intervention: Iron and Folic Acid (IFA; 60 mg Fe + 400 μg folic acid/d)
Number of subjects: 1320

Group type: COMPARATOR
Intervention: Control (Placebo; 200 mg Ca/d)
Number of subjects: 1320
Study: 24916605

Group type: EXPERIMENTAL
Intervention: Self‐Administered Comorbidity Questionnaire (SACQ)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: SACQ-AL (activity-limiting conditions)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Back pain
Number of subjects: 300
Study: 24004918

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (32 to 35°C)
Number of subjects: 600
Study: 20965611

Group type: EXPERIMENTAL
Intervention: Needleless injection device with protection cap (test group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional 3‐way stopcock (comparator group)
Number of subjects: 64
Study: 19276255

Group type: EXPERIMENTAL
Intervention: Weekly bolus irinotecan, 5-fluorouracil, and leucovorin (IFL)
Number of subjects: 1264

Group type: COMPARATOR
Intervention: Weekly bolus 5-fluorouracil/leucovorin
Number of subjects: 1264
Study: 17225709

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endovascular aortic aneurysm repair
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical reconstruction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty and stenting
Number of subjects: 0
Study: 15080782

Group type: EXPERIMENTAL
Intervention: Plasma aldosterone concentration (PAC) to active renin concentration (ARC) ratio
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Plasma aldosterone concentration (PAC) to active renin concentration (ARC) ratio with PAC > or =200 ng/l
Number of subjects: 50
Study: 11306209

Group type: EXPERIMENTAL
Intervention: 17beta-estradiol (1 mg/day) combined with dydrogesterone (5, 10 or 20 mg/day)
Number of subjects: 214
Study: 9704773

Group type: EXPERIMENTAL
Intervention: Cytokines (interleukin‐1beta and interleukin‐8)
Number of subjects: 2
Study: 8058148

Group type: EXPERIMENTAL
Intervention: Dezinamide (DZM)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 2648510

Group type: EXPERIMENTAL
Intervention: Regime A: Rifampicin, Isoniazid, Streptomycin, Pyrazinamide for 2 months followed by Rifampicin and Isoniazid for 4 months (total 6 months treatment)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Regime B: Rifampicin, Isoniazid, Streptomycin, Pyrazinamide for 2 months followed by Rifampicin and Isoniazid for 5 months (total 9 months treatment)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 141
Study: 31065839

Group type: EXPERIMENTAL
Intervention: Information booklet about prostate cancer treatment options prior to biopsy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no information provided)
Number of subjects: 98
Study: 30920186

Group type: EXPERIMENTAL
Intervention: High altitude (HA) on day 2
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High altitude (HA) on day 7
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High altitude (HA) on day 13
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High altitude (HA) on day 19
Number of subjects: 17

Group type: COMPARATOR
Intervention: Model prediction on HA2
Number of subjects: 17

Group type: COMPARATOR
Intervention: Model prediction on HA7
Number of subjects: 17

Group type: COMPARATOR
Intervention: Model prediction on HA13
Number of subjects: 17

Group type: COMPARATOR
Intervention: Model prediction on HA19
Number of subjects: 17
Study: 28396144

Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides (GOS) 15 g daily for 12 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 44